oral anticoagulants

Temporal Trends in Oral Anticoagulant Use and Clinical Outcomes Among Older Adults with Atrial Fibrillation: Insights from a Danish Nationwide Study and Contemporary Evidence

By MedXY 07/16/2026

Recent decades saw increased anticoagulant use and reduced stroke risk in elderly AF patients, especially with DOACs, but bleeding risks rise notably in very elderly patients, highlighting tailored management needs.

Cardiology Internal Medicine news

NSAID Co-prescription in Atrial Fibrillation: Doubling the Bleeding Burden Across All Oral Anticoagulants

By MedXY 01/04/2026

A nationwide cohort study demonstrates that NSAID use in patients with atrial fibrillation on oral anticoagulants nearly doubles the risk of hospital-diagnosed bleeding, with significant risks observed across all anticoagulant types and multiple anatomical sites.

Cardiology news

Widespread Anticoagulation Has Lowered Stroke but Not Intracranial Bleeding in the Very Elderly: Insights from a Danish Nationwide AF Cohort (1999–2022)

By MedXY 11/29/2025

Danish registry data (1999–2022) show large reductions in stroke across age groups with widespread oral anticoagulant (OAC) uptake, but only modest stroke gains and rising intracerebral hemorrhage in patients ≥85 years, highlighting the need for individualized strategies in the very elderly.

Cardiology Clinical Updates news

Continued versus Discontinued Oral Anticoagulant Therapy for Unprovoked Venous Thromboembolism: A Target Trial Emulation and Evidence Synthesis

By MedXY 11/22/2025

Continued oral anticoagulant therapy after ≥90 days for unprovoked VTE significantly lowers recurrence and mortality despite increased bleeding risk, offering a net clinical benefit consistent across anticoagulant types and treatment durations.

Cardiology Specialties

Reevaluating Long-Term Anticoagulation After Atrial Fibrillation Ablation: Insights from the ALONE-AF Randomized Trial

By MedXY 09/01/2025

The ALONE-AF trial reveals that discontinuation of oral anticoagulants post-successful atrial fibrillation ablation may reduce stroke, systemic embolism, and major bleeding compared to continued therapy, informing anticoagulation strategies in selected patients.